Results 131 to 140 of about 9,856 (174)

Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study. [PDF]

Blood Adv
Pastoret C, Yang J, Feith DJ, Roussel M, Moignet A, Dighe S, Solga MD, Marchand T, Visser G, Gasparini VR, Teramo A, Zambello R, Loughran TP, Lamy T.   +13 more
europepmc   +1 more source

Structural basis for NKG2A/CD94 recognition of HLA-E [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2008
The NKG2x/CD94 (x = A, C, E) natural killer-cell receptors perform an important role in immunosurveillance by binding to HLA-E complexes that exclusively present peptides derived from MHC class I leader sequences, thereby monitoring MHC class I expression.
Roland Strong, Brett K Kaiser, Strong Roland K   +2 more
exaly   +3 more sources

Intratumoral co‐injection of NK cells and NKG2A ‐neutralizing monoclonal antibodies

EMBO Molecular Medicine, 2023
Abstract NK‐cell reactivity against cancer is conceivably suppressed in the tumor microenvironment by the interaction of the inhibitory receptor NKG2A with the non‐classical MHC‐I molecules HLA‐E in humans or Qa‐1 b in mice.
Carmen Molina, Assunta Cirella, Ignacio Melero   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies

Journal of the American Society for Mass Spectrometry, 2021
NK group 2 member A (NKG2A), an immune checkpoint inhibitor, is an emerging therapeutic target in immuno-oncology. NKG2A forms a heterodimer with CD94 on the cell surface of NK and a subset of T cells and recognizes the nonclassical human leukocyte antigen (HLA-E) in humans.
Guodong Chen, Richard Y-C Huang, Natalie Bezman   +2 more
exaly   +3 more sources

NKG2A blocks the anti-metastatic functions of natural killer cells

Cancer Cell, 2023
Pancreatic ductal adenocarcinoma (PDAC)-derived liver metastasis represents a major unmet medical need. Liu et al. show that circulating tumor cells (CTCs) from the hepatic portal vein (HPV), and not from primary or metastatic sites, are protected from natural killer (NK) cells through the NKG2A/HLA-E axis.
Florent, Carrette, Eric, Vivier
openaire   +2 more sources

Permanent silencing of NKG2A expression for cell-based therapeutics

Journal of Molecular Medicine, 2008
Natural killer (NK) and T-cell cytotoxicity is significantly reduced by signaling via CD94/NKG2A receptors. High levels of NKG2A on NK cells have been shown to compromise the graft-versus-leukemia effect in hematopoietic stem cell transplantation.
Constança, Figueiredo, Axel, Seltsam, Rainer, Blasczyk   +2 more
openaire   +2 more sources

NKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody

Molecular Therapy
Natural killer (NK) cells eliminate infected or cancer cells via their cytotoxic capacity. NKG2A is an inhibitory receptor on NK cells and cancer cells often overexpress its ligand HLA-E to evade NK cell surveillance. Given the successes of immune checkpoint blockade in cancer therapy, NKG2A is an interesting novel target.
Ying Gong, Gérard Bos
exaly   +3 more sources

Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board

Trends in Immunology, 2019
Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731-1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors.
Mingari, Maria Cristina, Pietra, Gabriella, Moretta, Lorenzo   +2 more
openaire   +2 more sources

The NKG2A immune checkpoint — a new direction in cancer immunotherapy

Nature Reviews Clinical Oncology, 2019
Inhibition of the NKG2A immune checkpoint restores natural killer cell and T cell effector function in preclinical cancer models. In addition, NKG2A blockade in combination with other therapeutic antibodies is showing encouraging responses in a subset of patients with metastatic colorectal or head and neck cancer.
Benjamin C, Creelan, Scott J, Antonia
openaire   +2 more sources

Is CD94/NKG2A a novel target for lymphoid malignancies immunotherapy?

Blood, 2006
Abstract Background: Natural killer (NK)-cell receptors (NKRs) on CD8+ T cells can modulate antigen-specific T cell activity but their function and rules that govern their expression remain unclear. Among NKRs heterodimers CD94-NKG2 form either an inhibitory or an activating receptor, depending on whether CD94 associates with NKG2A or ...
Kiełbiński, Marek, Tomaszewska-Toporska, Beata, Kapelko-Słowik, Katarzyna, Kuliczkowski, Kazimierz   +3 more
openaire   +2 more sources